Keywords: migraine, combo-therapy, evaluated, pozen, glaxosmithkline, investigational, combination
Migraine combo-therapy evaluated
Article | 03 July 2006
Pozen and GlaxoSmithKline's investigational, combination migraine product has demonstrated effective treatment of migraine-associated neck pain/discomfort and sinus pain/pressure, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
